{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:32:12Z","timestamp":1749713532157,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008769","name":"Julius-Maximilians-Universit\u00e4t W\u00fcrzburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bayerisch\u2013Tschechische Hochschulagentur"},{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In addition to randomized clinical trials, consideration of Real-World Evidence is necessary for mirroring clinical reality. However, processing such evidence for large numbers of patients often requires considerable time and effort. This is particularly true for rare tumor diseases such as multiple myeloma (MM) or for adverse effects that occur even more rarely. In such cases, artificial intelligence is able to efficiently detect patients with rare conditions. One of these rare adverse events, and the most discussed, following bone protective treatment in MM is medication-related osteonecrosis of the jaw (MRONJ). The association of bone protective treatment to MM outcome has been intensively studied. However, the impact of MRONJ resulting from such treatment on MM prognosis and outcome is poorly understood. In this retrospective study, we therefore investigated the long-term effects of MRONJ. We used natural language processing (NLP) to screen individual data of 2389 MM patients to find 50 out of 52 patients with MRONJ matching our inclusion criteria. To further improve data quality, we then performed propensity score matching. In comparison to MM patients without MRONJ, we found a significantly longer overall survival (median 126 vs. 86\u00a0months) despite slightly worse clinical features.\n<\/jats:p>","DOI":"10.1007\/s10238-023-01100-6","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T17:01:36Z","timestamp":1696698096000},"page":"5215-5226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence"],"prefix":"10.1007","volume":"23","author":[{"given":"Max","family":"Bittrich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Hetterich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio G.","family":"Solimando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Loda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Danhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Straub","family":"Anton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kerscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Beilhack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,7]]},"reference":[{"issue":"5","key":"1100_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u201386.","journal-title":"Int J Cancer"},{"issue":"4","key":"1100_CR2","first-page":"596","volume":"22","author":"V Chatziravdeli","year":"2022","unstructured":"Chatziravdeli V, Katsaras GN, Katsaras D, Doxani C, Stefanidis I, Zintzaras E. A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives. J Musculoskelet Neuronal Interact. 2022;22(4):596\u2013621.","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"12","key":"1100_CR3","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","volume":"18","author":"F Jadu","year":"2007","unstructured":"Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol. 2007;18(12):2015\u20139.","journal-title":"Ann Oncol"},{"issue":"10","key":"1100_CR4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.bjoms.2015.10.006","volume":"53","author":"F Jarnbring","year":"2015","unstructured":"Jarnbring F, Kashani A, Bj\u00f6rk A, et al. Role of intravenous dosage regimens of bisphosphonates in relation to other aetiological factors in the development of osteonecrosis of the jaws in patients with myeloma. Br J Oral Maxillofac Surg. 2015;53(10):1007\u201311.","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"8","key":"1100_CR5","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","volume":"71","author":"C Tsao","year":"2013","unstructured":"Tsao C, Darby I, Ebeling PR, et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg. 2013;71(8):1360\u20136.","journal-title":"J Oral Maxillofac Surg"},{"issue":"4","key":"1100_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jcms.2011.05.003","volume":"40","author":"S Otto","year":"2012","unstructured":"Otto S, Schreyer C, Hafner S, et al. Bisphosphonate-related osteonecrosis of the jaws\u2014characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg. 2012;40(4):303\u20139.","journal-title":"J Craniomaxillofac Surg"},{"issue":"2","key":"1100_CR7","first-page":"42","volume":"7","author":"N Raje","year":"2019","unstructured":"Raje N, Terpos E, Jandial DD. Response to comment-osteonecrosis of the jaw in Myeloma patients receiving denosumab or zoledronic acid. Comment on pivotal trial by Raje et al. published in lancet oncology. Dent J (Basel). 2019;7(2):42.","journal-title":"Dent J (Basel)"},{"issue":"10","key":"1100_CR8","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update. J Oral Maxillofac Surg. 2014;72(10):1938\u201356.","journal-title":"J Oral Maxillofac Surg"},{"key":"1100_CR9","doi-asserted-by":"publisher","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American association of oral and maxillofacial surgeons\u2019 position paper on medication-related osteonecrosis of the jaw\u20132022 update. J Oral Maxillofac Surg. 2022. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008.","DOI":"10.1016\/j.joms.2022.02.008"},{"issue":"9","key":"1100_CR10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115\u20137.","journal-title":"J Oral Maxillofac Surg"},{"issue":"3","key":"1100_CR11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370\u201381.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1100_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/bjh.12861","volume":"166","author":"GH Jackson","year":"2014","unstructured":"Jackson GH, Morgan GJ, Davies FE, et al. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. Br J Haematol. 2014;166(1):109\u201317.","journal-title":"Br J Haematol"},{"issue":"7","key":"1100_CR13","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/jcm8070999","volume":"8","author":"S Loda","year":"2019","unstructured":"Loda S, Krebs J, Danhof S, et al. Exploration of artificial intelligence use with ARIES in multiple Myeloma research. J Clin Med. 2019;8(7):999.","journal-title":"J Clin Med"},{"issue":"9","key":"1100_CR14","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373.","journal-title":"Leukemia"},{"issue":"8","key":"1100_CR15","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"key":"1100_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1200\/CCI.19.00167","volume":"4","author":"JH Ryu","year":"2020","unstructured":"Ryu JH, Zimolzak AJ. Natural language processing of serum protein electrophoresis reports in the veterans affairs health care system. JCO Clin Cancer Inform. 2020;4:749\u201356.","journal-title":"JCO Clin Cancer Inform"},{"issue":"Pt 1","key":"1100_CR17","first-page":"565","volume":"107","author":"H Xu","year":"2004","unstructured":"Xu H, Anderson K, Grann VR, Friedman C. Facilitating cancer research using natural language processing of pathology reports. Stud Health Technol Inform. 2004;107(Pt 1):565\u201372.","journal-title":"Stud Health Technol Inform"},{"issue":"1","key":"1100_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/tbj.13718","volume":"26","author":"KS Hughes","year":"2020","unstructured":"Hughes KS, Zhou J, Bao Y, Singh P, Wang J, Yin K. Natural language processing to facilitate breast cancer research and management. Breast J. 2020;26(1):92\u20139.","journal-title":"Breast J"},{"issue":"1","key":"1100_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/0272989X11400418","volume":"32","author":"JC Denny","year":"2012","unstructured":"Denny JC, Choma NN, Peterson JF, et al. Natural language processing improves identification of colorectal cancer testing in the electronic medical record. Med Decis Making. 2012;32(1):188\u201397.","journal-title":"Med Decis Making"},{"issue":"11","key":"1100_CR20","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.jfma.2021.01.015","volume":"120","author":"SY Lu","year":"2021","unstructured":"Lu SY, Ma MC, Wang MC, Hsue SS. The status of jaw lesions and medication-related osteonecrosis of jaw in patients with multiple myeloma. J Formos Med Assoc. 2021;120(11):1967\u201376.","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"1100_CR21","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1007\/s00520-022-06839-4","volume":"30","author":"H Hata","year":"2022","unstructured":"Hata H, Imamachi K, Ueda M, et al. Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study. Support Care Cancer. 2022;30:4505\u201314. https:\/\/doi.org\/10.1007\/s00520-022-06839-4.","journal-title":"Support Care Cancer"},{"issue":"12","key":"1100_CR22","doi-asserted-by":"publisher","first-page":"9693","DOI":"10.1007\/s00520-022-07434-3","volume":"30","author":"H Hata","year":"2022","unstructured":"Hata H, Imamachi K, Ueda M, et al. Response to: Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points. Support Care Cancer. 2022;30(12):9693\u20135.","journal-title":"Support Care Cancer"},{"key":"1100_CR23","doi-asserted-by":"crossref","unstructured":"Cabras M, Gambino A, Conrotto D, et al. Survival of metastatic cancer and myeloma patients after diagnosis of Osteonecrosis of Jaws (ONJ). Potential impact on ONJ treatment strategies. Qeios. 2021.","DOI":"10.32388\/IKLIWH"},{"issue":"5","key":"1100_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41408-020-0323-4","volume":"10","author":"D Pulte","year":"2020","unstructured":"Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020;10(5):56.","journal-title":"Blood Cancer J"},{"key":"1100_CR25","doi-asserted-by":"publisher","unstructured":"Fusco V, Cabras M, Gambino A, et al. Expected survival of cancer and myeloma patients undergoing bisphosphonates or denosumab. Potential impact on diagnosis and management of Osteonecrosis of Jaws (ONJ). preprint V1, Qeios. 2021. https:\/\/doi.org\/10.32388\/MQ2IYG.","DOI":"10.32388\/MQ2IYG"},{"issue":"1","key":"1100_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21\u201333.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"1100_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3816\/CLML.2010.n.080","volume":"10","author":"G Talamo","year":"2010","unstructured":"Talamo G, Farooq U, Zangari M, et al. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2010;10(6):464\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"1100_CR28","doi-asserted-by":"publisher","first-page":"7948","DOI":"10.18632\/aging.102301","volume":"11","author":"D Liu","year":"2019","unstructured":"Liu D, Ma Z, Yang J, et al. Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study. Aging (Albany NY). 2019;11(18):7948\u201360.","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"1100_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Kumar S. Multiple Myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101\u201319.","journal-title":"Mayo Clin Proc"},{"issue":"21","key":"1100_CR30","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1182\/blood.V122.21.3090.3090","volume":"122","author":"E Terpos","year":"2013","unstructured":"Terpos E, Kanellias N, Moulopoulos LA, et al. Skeletal-related events in patients with multiple myeloma in the era of novel agents: low incidence of pathological fractures after treatment. Blood. 2013;122(21):3090.","journal-title":"Blood"},{"issue":"29","key":"1100_CR31","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple Myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279\u201389.","journal-title":"J Clin Oncol"},{"issue":"34","key":"1100_CR32","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23(34):8580\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1100_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/annonc\/mdn554","volume":"20","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20(1):117\u201320.","journal-title":"Ann Oncol"},{"issue":"11","key":"1100_CR34","first-page":"658","volume":"35","author":"C Then","year":"2012","unstructured":"Then C, Hoerauf N, Otto S, et al. Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation. Oncol Res Treatm. 2012;35(11):658\u201364.","journal-title":"Oncol Res Treatm"},{"issue":"4","key":"1100_CR35","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","volume":"35","author":"V Thumbigere-Math","year":"2012","unstructured":"Thumbigere-Math V, Tu L, Huckabay S, et al. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol. 2012;35(4):386\u201392.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"1100_CR36","first-page":"13","volume":"21","author":"D Auzina","year":"2019","unstructured":"Auzina D, Slaidina A, Sevastjanova M, Erts R, Lejnieks A, Lejniece S. A population based study of multiple myeloma patients with medication-related osteonecrosis of the jaw. Stomatologija. 2019;21(1):13\u20137.","journal-title":"Stomatologija"},{"issue":"1","key":"1100_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40902-016-0099-4","volume":"39","author":"WS Choi","year":"2017","unstructured":"Choi WS, Lee JI, Yoon HJ, Min CK, Lee SH. Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma. Maxillofac Plast Reconstr Surg. 2017;39(1):1.","journal-title":"Maxillofac Plast Reconstr Surg"},{"issue":"6","key":"1100_CR38","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/bjh.17256","volume":"193","author":"E Terpos","year":"2021","unstructured":"Terpos E, Ntanasis-Stathopoulos I. Controversies in the use of new bone-modifying therapies in multiple myeloma. Br J Haematol. 2021;193(6):1034\u201343.","journal-title":"Br J Haematol"},{"issue":"5","key":"1100_CR39","first-page":"575","volume":"17","author":"M Kos","year":"2008","unstructured":"Kos M, \u0141uczak K. Osteonecrosis of the jaws associated with administration of bisphosphonates. Adv Clin Exp Med. 2008;17(5):575\u201381.","journal-title":"Adv Clin Exp Med"},{"issue":"1","key":"1100_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1746-160X-6-11","volume":"6","author":"C Walter","year":"2010","unstructured":"Walter C, Al-Nawas B, Frickhofen N, et al. Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med. 2010;6(1):1\u20138.","journal-title":"Head Face Med"},{"key":"1100_CR41","doi-asserted-by":"publisher","unstructured":"Fusco V, Campisi G, de Boissieu P, et al. Osteonecrosis of the jaw in myeloma patients receiving denosumab or zoledronic acid. A commentary of the pivotal trial by Raje et al. published on lancet oncology. Dent J (Basel). 2018;6(3). https:\/\/doi.org\/10.3390\/dj6030042.","DOI":"10.3390\/dj6030042"},{"key":"1100_CR42","unstructured":"Schiegnitz, E, Al-Nawas, B, Hoefert, S, et al. S3-Leitlinie Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ). AWMF Online. 2018:007\u201391."},{"key":"1100_CR43","doi-asserted-by":"crossref","unstructured":"M\u00fccke, T, Krestan, CR, Mitchell, DA, Kirschke, JS, Wutzl, A, (eds). Bisphosphonate and medication-related osteonecrosis of the jaw: a review. Seminars in musculoskeletal radiology. Thieme Medical Publishers; 2016.","DOI":"10.1055\/s-0036-1592367"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01100-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01100-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01100-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T16:22:19Z","timestamp":1702743739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01100-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1100"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01100-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"type":"electronic","value":"1591-9528"}],"subject":[],"published":{"date-parts":[[2023,10,7]]},"assertion":[{"value":"17 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}